logo
Download Download 3
Views 13

Details

Highlights

  • Economic evidence (cost-effectiveness information) can be used to inform policy-making process in supporting the movement towards universal health coverage. Published literature has focused on methods to set a cost-effectiveness threshold (CET) which can be used to guide the cost-effectiveness of a health technology. Higher CET could increase the opportunity that health technologies will be reimbursed by a healthcare payer. Other published literature focused on the discussion of whether CET should be increased.
  • Although there has been a debate around an optimal CET and a significant development of methodologies for estimating CET, to our knowledge, no other country has changed their existing explicit CET. Thailand is in a unique position to help answer the question of what happened when CET was increased. The objectives were to explore the impact of increasing CET on the submitted medicine price and the reimbursement decision to the National List of Essential Medicine.
  • The current findings showed that a change in CET did not significantly influence the likelihood of a positive benefit package listing recommendation, or the medicine prices set by manufacturers for public payers. The findings shed light to the potential impact of increasing a CET and highlighted a need for further research into the role of CET in informing policy decisions (with a qualitative approach), to better guide CET policy in Thailand and globally.